These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 14660268

  • 1. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F, Borenstein M, Kirsner R, Kerdel F.
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
    Heikkilä H, Ranki A, Cajanus S, Karvonen SL.
    Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 7. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
    Lisby S, Gniadecki R.
    Acta Derm Venereol; 2004 Feb; 84(3):247-8. PubMed ID: 15202853
    [No Abstract] [Full Text] [Related]

  • 8. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
    Winterfield L, Menter A.
    Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
    [Abstract] [Full Text] [Related]

  • 9. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.
    Nishizawa A, Satoh T, Yokozeki H.
    Acta Derm Venereol; 2012 Jul; 92(4):360-1. PubMed ID: 22565356
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.
    Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF, Van Voorhees AS, National Psoriasis Foundation Medical Board.
    J Am Acad Dermatol; 2010 Apr; 62(4):655-62. PubMed ID: 19665821
    [Abstract] [Full Text] [Related]

  • 14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 15. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
    Dogra S, Bishnoi A, Narang T, Handa S.
    Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab.
    Stinco G, Piccirillo A, Errichetti E, Bergamo S, Patrone P.
    Eur J Dermatol; 2014 Jul; 24(3):387-90. PubMed ID: 24721883
    [No Abstract] [Full Text] [Related]

  • 17. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [Abstract] [Full Text] [Related]

  • 19. Erythrodermic psoriasis and secukinumab: Our clinical experience.
    Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL.
    Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
    [No Abstract] [Full Text] [Related]

  • 20. Psoriasis-induced postoperative cardiac failure.
    Jha PK, Das SR, Musleh GS, Lakshmanan S, Kingston TP, Deiraniya AK.
    Ann Thorac Surg; 2005 Apr; 79(4):1390-1. PubMed ID: 15797087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.